This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Par, Paddock file reply brief supporting dismissal of FTC AndroGel suit

( March 3, 2014, 23:00 GMT | Official Statement) -- MLex Summary: Par Pharmaceuticals and Paddock Holdings have filed a reply brief supporting their motion to dismiss the US Federal Trade Commission's complaint alleging a pay-for-delay agreement involving the drug AndroGel. The companies argue that their settlement is protected under the Noerr-Pennington doctrine because there is no precedent in Noerr that provides a basis for "distinguishing jointly proposed terms of a court order from terms achieved adversarially."See document below....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections